Simulations Plus, Inc. (NASDAQ:SLP - Get Free Report) shares fell 4.2% on Tuesday . The company traded as low as $33.01 and last traded at $32.74. 53,890 shares were traded during trading, a decline of 71% from the average session volume of 188,230 shares. The stock had previously closed at $34.16.
Wall Street Analysts Forecast Growth
SLP has been the subject of a number of analyst reports. William Blair reiterated an "outperform" rating on shares of Simulations Plus in a research note on Wednesday, January 8th. StockNews.com lowered Simulations Plus from a "hold" rating to a "sell" rating in a research note on Monday. Finally, KeyCorp lifted their target price on Simulations Plus from $32.00 to $40.00 and gave the company an "overweight" rating in a research note on Wednesday. One research analyst has rated the stock with a sell rating, one has given a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $50.00.
Get Our Latest Stock Report on SLP
Simulations Plus Price Performance
The stock has a 50-day moving average price of $28.55 and a two-hundred day moving average price of $30.09. The stock has a market cap of $657.43 million, a PE ratio of 81.73 and a beta of 1.13.
Simulations Plus (NASDAQ:SLP - Get Free Report) last posted its earnings results on Thursday, April 3rd. The technology company reported $0.31 EPS for the quarter, beating analysts' consensus estimates of $0.25 by $0.06. The firm had revenue of $22.43 million during the quarter, compared to the consensus estimate of $21.93 million. Simulations Plus had a return on equity of 6.84% and a net margin of 10.97%. The company's quarterly revenue was up 22.5% compared to the same quarter last year. During the same period in the prior year, the company earned $0.20 EPS. Equities research analysts expect that Simulations Plus, Inc. will post 1.09 earnings per share for the current year.
Insider Buying and Selling
In related news, Director Walter S. Woltosz sold 20,000 shares of the firm's stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $33.91, for a total value of $678,200.00. Following the completion of the sale, the director now directly owns 3,402,584 shares in the company, valued at $115,381,623.44. This trade represents a 0.58 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 19.40% of the stock is currently owned by company insiders.
Institutional Investors Weigh In On Simulations Plus
Institutional investors have recently made changes to their positions in the company. Barclays PLC lifted its stake in Simulations Plus by 390.6% in the third quarter. Barclays PLC now owns 28,473 shares of the technology company's stock worth $911,000 after purchasing an additional 22,669 shares during the last quarter. Proficio Capital Partners LLC purchased a new position in Simulations Plus during the 4th quarter valued at $719,000. Geode Capital Management LLC grew its position in Simulations Plus by 4.4% in the 3rd quarter. Geode Capital Management LLC now owns 448,618 shares of the technology company's stock valued at $14,367,000 after acquiring an additional 18,924 shares during the last quarter. State Street Corp increased its stake in Simulations Plus by 4.7% in the third quarter. State Street Corp now owns 640,303 shares of the technology company's stock worth $20,503,000 after purchasing an additional 28,953 shares during the period. Finally, JPMorgan Chase & Co. lifted its position in shares of Simulations Plus by 106.0% during the third quarter. JPMorgan Chase & Co. now owns 47,365 shares of the technology company's stock worth $1,517,000 after purchasing an additional 24,371 shares during the last quarter. Institutional investors own 78.08% of the company's stock.
Simulations Plus Company Profile
(
Get Free Report)
Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.
Further Reading
Before you consider Simulations Plus, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Simulations Plus wasn't on the list.
While Simulations Plus currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
